Search

everythinglearnresearchcommunity

for

Search:↓

The user has been using RU58841 with minoxidil for hair loss, which helped but caused itchiness, and is considering increasing the dose and adding topical finasteride to the treatment. They are inquiring if they can mix RU58841 and finasteride into one solution with Stemoxydine or if they need separate solutions and which to apply first.

Yunce Medical, a Chinese company, is developing hair multiplication technology similar to Stemson Therapeutics, with potential for quicker availability due to favorable regulations. Users express skepticism and hope for future advancements in hair loss treatments.

The conversation discusses using a multimodal approach to treat androgenic alopecia, including substances like gamma-linolenic acid, DHA, sulforaphane, melatonin, cetirizine, astaxanthin, fisetin, apigenin, curcumin, limonene, genistein, and berberine. Users also mention using ketoconazole, minoxidil, and low-level laser therapy (LLLT) as part of their hair loss treatment regimens.

A group buy for testing a compound targeting Twist1 protein as a potential hair loss treatment. Inhibiting Twist1, which keeps hair follicles in growth phase, may prevent hair loss with minimal side effects.

BionicBell discussed using Bimatoprost, a medication typically for eyelash growth, for hair loss and mentioned a compounding pharmacy that can mix it with other ingredients like minoxidil and finasteride. They are seeking advice on using topical finasteride for female pattern baldness and are considering a custom foam combination to maximize hair growth results.

The conversation discusses interest in peptides for hair loss, specifically mentioning ahkCU and ghkCU. A user is considering adding ghkCU to their treatment regimen.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

A product called HairMDL includes Minoxidil, Dutasteride, Latanoprost, caffeine, Tretinoin, and Triamcinolone. Users are curious about its effectiveness and safety, particularly regarding the topical steroid Triamcinolone.

Experimenting with trestolone as a treatment for hair loss in an attempt to avoid DHT-related treatments such as finasteride and dutasteride, and discussing the potential effects of its receptor selectivity on the androgen receptors in the scalp.

Mixing minoxidil and stemoxydine is not recommended due to potential dilution and reduced effectiveness. Applying them separately with a time gap is suggested.

The user is seeking an alternative to DualGen 15 that includes Minoxidil and Retinol but is less sticky and more convenient to use. They find the current product inconvenient due to its stickiness and long wait time before washing.

A Phase II clinical trial for TDM-105795 has started recruiting in the US, and it might be a promising treatment for hair loss. Many hair loss drugs, including this one, originate from China.

2-Deoxy-D-Ribose is discussed as a potential hair loss treatment, but skepticism exists due to lack of human testing. The original poster uses a combination of topical Minoxidil, oral Finasteride, topical RU58841, and other treatments, reporting some hair regrowth but not significant results.

A user mixed 3g of RU58841 with Kirkland Minoxidil and noticed a gooey precipitate forming. They are seeking advice on what went wrong.

A user is seeking advice on creating a homemade finasteride foam similar to over-the-counter Minoxidil foam, due to issues with glycerin and propylene glycol in their current solutions. They are considering using a mixture of ethanol/alcohol and water for the foam.

Mixing topical finasteride with essengen f and stemoxydine creates 0.25mg dose in 2ml. Minoxidil max suggests mixing 8.5ml essengen f with 60ml solvent for 0.25mg dose in 1ml.

OP is considering using Stemoxydine or the Ordinary Multi Peptide Hair Serum as a carrier for topical finasteride, avoiding minoxidil due to palpitations. They plan to crush finasteride pills into a 30 ml solution.

User discusses group buy for finerenone, a third-gen mineralocorticoid antagonist for hair loss treatment. Finerenone inhibits TGFb, NOX, and ROS, and improves renal and cardiac function; topical dose should be no more than 10mg per day.

The user is using Dutasteride, Nizoral, and RU58841 for hair loss and is considering mixing RU58841 with Stemoxydine for better scalp coverage but is concerned about the potential degradation of RU58841 when mixed with a water-based solution. They are seeking advice on the feasibility of this mixture.

FOL-005 claims to be more effective than Minoxidil and Finasteride but lacks anti-DHT properties, leading to potential reduced efficacy over time. Concerns are raised about misleading marketing and the safety of alternative treatments like Pyrilutamide and Clascoterone.

A user is seeking advice on creating a topical solution combining minoxidil, finasteride, and tretinoin for hair loss, and is unsure about optimal concentrations and availability. Another user shares their custom formula with tretinoin 0.015%, finasteride 0.025%, and minoxidil 5%, and mentions taking oral dutasteride 0.25mg daily.

The user is seeking a topical spray combining finasteride, minoxidil, and RU58841 or dutasteride due to side effects from oral treatments. They believe an all-in-one topical solution would be easier for long-term use.

The conversation discusses the delay in bringing FAK inhibitors and Stanford's hydrogel to market for hair transplants, with a preference for FAK inhibitors over Verteporfin due to their superior potential in preventing scarring. The user expresses frustration over the slow progress and hopes for faster development by companies like FAKnostics.

The conversation discusses the lack of public information on the chemical structure of PP405, a hair loss treatment, and the challenges of synthesizing it without a patent. It also explores a patent related to hydrogen-based topical formulations for reducing oxidative stress and inflammation.

The post and conversation are about skepticism towards a new hair loss treatment containing 2-deoxy-D-ribose, copper peptides, and exosomes, with concerns about the legitimacy of the product and its website. The treatment's effectiveness and authenticity are questioned due to lack of testing and transparency.

The conversation is about trying DS Labs SOD supplements for hair loss, which contain ingredients like Genistein, B-sitosterol, and Biotin. The user is considering adding these supplements to their existing hair care routine.

The conversation discusses hair regrowth using 2-deoxy-d-ribose (2DDR) combined with minoxidil, with some users noting new hair growth. The original poster has been using minoxidil for 12 years and is considering combining 2DDR with finasteride, despite past side effects.

The conversation discusses skepticism about "5 in 1" and "3 in 1" hair loss treatments, which combine Dutasteride or Finasteride with Minoxidil, being overpriced and potentially ineffective. Users suggest buying individual components separately for cost savings and question the effectiveness of low concentrations in these combined products.

Amplifica has not provided updates on SCUBE3 and AMP-303, raising concerns about their trial outcomes. Users also mention other treatments like Minoxidil, finasteride, RU58841, PP405, and ET-03.

Researching whether pyri and enza, which are stereoisomers of each other, share the same features related to CNS penetration/GABA Inhibition; safety and efficacy when used topically at 0.5-1%; and cost comparison between the two treatments.